OTC Zantac prevention claim for heartburn, dyspepsia, indigestion proposed in U.K..
This article was originally published in The Tan Sheet
Executive Summary
RANITIDINE OTC TO GAIN HEARTBURN PREVENTION INDICATION IN U.K., according to the Medicines Control Agency's twice-yearly consultation letter on proposals to amend the prescription-only medicines order, released July 24. "Ranitidine has been available as a pharmacy medicine for the short-term symptomatic relief of heartburn, dyspepsia, indigestion, acid indigestion and hyperacidity since 1994," the letter states. "In line with the [Committee on Safety of Medicines'] previous decisions on such substances, we propose to extend the availability of ranitidine as a pharmacy medicine for the prevention of these symptoms when consuming food or drink." Pharmacy medicines are sold behind-the-counter in the U.K.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning